A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study To Evaluate Safety, Tolerability, Pharmacometrics, And Efficacy Of Dnth103 In Adults With Multifocal Motor Neuropathy (Momentum)
Posted Date: Sep 11, 2025
- Investigator: Hani Kushlaf
- Specialties: Neurology, Neuromuscular Disorders
- Type of Study: Drug
This is a multicenter, randomized, placebo-controlled, double-blinded treatment, parallel-group study followed by an open-label extension (OLE). The study includes a safety follow-up period. To evaluate the safety and tolerability of DNTH103 in participants with multifocal motor neuropathy (MMN) up to Week 17
Criteria:
Adult Males And Females, 18 To 75 Years Of Age (Inclusive) At Screening. A Diagnosis Of Definite Or Probable Mmn Per The European Federation Of Neurological Societies (Efns) / Peripheral Nerve Society (Pns)(Efns/Pns) 2010 Guidelines At Screening And Confirmed By The Icc. Responsive To Ig Treatment As Determined By (1) Historical Document Review As Confirmed By The Icc Or (2) Evidence Of Cd During The Prospective Ig Dependency Period.
Keywords:
Mmn
For More Information:
Sara Reiber
5135580163
searss2@ucmail.uc.edu